All In Biotech

Drug Trial Radar · NCT02600507

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

Last checked: Nov 20, 2026Latest source record: May 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 529 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

529

Actual

Start

Mar 7, 2016

Primary completion

Jul 2, 2020

Study completion Jul 2, 2020

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Nov 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.

Conditions

  • Bipolar Depression

Interventions

  • Lumateperone (ITI-007)Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline to Day 43

Locations

71 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Rogers, Arkansas

  • Clinical Site

    Cerritos, California

  • Clinical Site

    Costa Mesa, California

  • Clinical Site

    Culver City, California

  • Clinical Site

    Garden Grove, California

  • Clinical Site

    Glendale, California

  • Clinical Site

    Lemon Grove, California

  • Clinical Site

    Oceanside, California

  • Clinical Site

    Pico Rivera, California

  • Clinical Site

    Riverside, California

  • Clinical Site

    San Diego, California

  • Clinical Site

    Santa Rosa, California

  • Clinical Site

    Sherman Oaks, California

  • Clinical Site

    Temecula, California

  • Clinical Site

    Jacksonville, Florida

  • Clinical Site

    Lauderhill, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Orange City, Florida

  • Clinical Site

    Orlando, Florida

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Savannah, Georgia

  • Clinical Site

    Chicago, Illinois

  • Clinical Site

    Lake Charles, Louisiana

  • Clinical Site

    Baltimore, Maryland

  • Clinical Site

    O'Fallon, Missouri

  • Clinical Site

    St Louis, Missouri

  • Clinical Site

    Las Vegas, Nevada

  • Clinical Site

    Berlin, New Jersey

  • Clinical Site

    Cherry Hill, New Jersey

  • Clinical Site

    Toms River, New Jersey

  • Clinical Site

    Cedarhurst, New York

  • Clinical Site

    New York, New York

  • Clinical Site

    Rochester, New York

  • Clinical Site

    Staten Island, New York

  • Clinical Site

    Charlotte, North Carolina

  • Clinical Site

    Cincinnati, Ohio

  • Clinical Site

    Dayton, Ohio

  • Clinical Site

    Garfield Heights, Ohio

  • Clinical Site

    Allentown, Pennsylvania

  • Clinical Site

    Philadelphia, Pennsylvania

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.